Farallon Capital Portfolio
Invests via Farallon Capital Management LLC | Managed by Farallon Capital Management LLC
Invests via Farallon Capital Management LLC
Managed by Farallon Capital Management LLC
Automatically Tracked
Company Profile
Founded in 1986 by Tom Steyer, Farallon Capital is a San Francisco-based alternative asset manager focused on value-oriented investing across public and private markets. The firm deploys multi-strategy capital into equities, credit, distressed, real assets and private equity alongside opportunistic special-situations investments. Institutional-facing, Farallon positions itself as a long-horizon, research-driven allocator that blends fundamental analysis with event-driven and relative-value tactics.
Founded in 1986 by Tom Steyer, Farallon Capital is a San Francisco-based alternative asset manager focused on value-oriented investing across public and private markets. The firm deploys multi-strategy capital into equities, credit, distressed, real assets and private equity alongside opportunistic special-situations investments. Institutional-facing, Farallon positions itself as a long-horizon, research-driven allocator that blends fundamental analysis with event-driven and relative-value tactics.
Investment Philosophy & Strategy
A long-horizon, multi-strategy allocator that emphasizes value-oriented, research-driven capital deployment across public and private markets. The approach blends fundamental equity and credit analysis with opportunistic distressed, event-driven and relative-value tactics to generate asymmetric returns. Capital allocation favors flexible positioning—strategic stakes in undervalued companies, credit exposures in stressed credits, real-asset hedges, and private investments where mispricing and operational upside exist. Risk management is active and portfolio-level, using diversification, liquidity overlays and position-sizing to protect capital while exploiting dislocations and special situations.
A long-horizon, multi-strategy allocator that emphasizes value-oriented, research-driven capital deployment across public and private markets. The approach blends fundamental equity and credit analysis with opportunistic distressed, event-driven and relative-value tactics to generate asymmetric returns. Capital allocation favors flexible positioning—strategic stakes in undervalued companies, credit exposures in stressed credits, real-asset hedges, and private investments where mispricing and operational upside exist. Risk management is active and portfolio-level, using diversification, liquidity overlays and position-sizing to protect capital while exploiting dislocations and special situations.
Disclaimer: This Portfolio is derived from and computed based on publicly available data from SEC filings.
Gain and growth charts are calculated per selected timeframe:
97.35%
Gain +0.57%
Monthly
0.77%
Yearly
9.59%
Drawdown
19.54%
$18.05B
Equity
Holdings
$18.05B
Investment
$12.53B
$20.39B
Profit +$98.92M
Realized
$14.88B
Unrealized
$5.52B
Dividends
$1.42B
Goals
Avg. 88.75% completed goals
Yearly
Gain > 8% 2026
Yearly
Loss < 12% 2026
Yearly
Loss < $100M 2026
Yearly
Gain < 20% 2026
Today
Compared To Yesterday
Gain
0.57%
Profit
$98.92M
Win %
59%
This Week
Compared To Last Week
Gain
-0.2%
Profit
-$36.75M
Win %
59%
This Month
Compared to last month
Gain
-1.33%
Profit
-$243.6M
Win %
59%
This Year
Compared to last year
Gain
4.41%
Profit
$761.97M
Win %
61%
PRME Prime Medicine Inc.
+10.86%
+$421,886.62 
ALMR Alamar Biosciences, Inc.
+10.7%
+$1.26M 
SMG Scotts Miracle-Gro Co.
+7.56%
+$330,880 
SGMT Sagimet Biosciences Inc.
+7.42%
+$232,400 
KLRA Kailera Therapeutics, Inc.
+6.33%
+$748,440 
TSHA Taysha Gene Therapies Inc.
+5.84%
+$461,250 
BC Brunswick Corporation
+5.18%
+$195,505 
BYND Beyond Meat Inc.
+4.51%
+$191.92 
WAY Waystar Holding Corp.
+4.43%
+$315,231 
AGIO Agios Pharmaceuticals Inc.
+4.39%
+$8.05M 
ABVX Abivax SA ADR
+4.36%
+$467,870 
AON Aon plc
+4.25%
+$16.18M 
ALVO Alvotech SA
+4.06%
+$600,531.75 
MAZE Maze Therapeutics Inc.
+3.96%
+$1.15M 
BBIO BridgeBio Pharma, Inc.
+3.74%
+$26.11M 
COGT Cogent Biosciences, Inc.
+3.69%
+$17,680 
UNH UnitedHealth Group Incorporated
+3.67%
+$18.46M 
TMO Thermo Fisher Scientific Inc.
+3.45%
+$24.36M 
NVO Novo Nordisk A/S Sponsored ADR
+3.33%
+$3.33M 
AZN AstraZeneca PLC American Depositary Shares
+3.28%
+$3.05M 
ENTA Enanta Pharmaceuticals Inc.
+3.09%
+$834,279.69 
AVTX Avalo Therapeutics Inc.
+2.79%
+$824,340 
IDXX IDEXX Laboratories, Inc.
+2.74%
+$130,455 
EXEL Exelixis Inc.
+2.72%
+$22.36M 
NVS Novartis AG Sponsored ADR
+2.7%
+$1.44M 
NTES NetEase, Inc. American Depositary Receipt
+2.59%
+$396,435 
GERN Geron Corporation
+2.52%
+$432 
BEAM Beam Therapeutics Inc.
+2.5%
+$6.05M 
NTRA NATERA INC (Common Stock) – ticker 45E
+2.49%
+$21.81M 
GH Guardant Health Inc.
+2.28%
+$1.2M 
SLDPW Solid Power, Inc. Warrant
+2.27%
+$162.13 
BSX Boston Scientific Corporation
+2.15%
+$9.73M 
KKR KKR & Co. Inc.
+1.94%
+$6.84M 
GNTX Gentex Corporation
+1.85%
+$76,615 
JOYY JOYY Inc. American Depositary Shares
+1.69%
+$973,566.08 
BIIB Biogen Inc.
+1.66%
+$274,770 
RANI Rani Therapeutics Holdings Inc.
+1.58%
+$219.42 
AXTA Axalta Coating Systems Ltd.
+1.51%
+$239,000 
TEVA Teva Pharmaceutical Industries Ltd. ADR
+1.45%
+$23,600 
LQDA Liquidia Corporation
+1.3%
+$3.68M 
WELL Welltower Inc.
+1.11%
+$2,580 
MSFT Microsoft Corp.
+0.99%
+$5.89M 
ROIV Roivant Sciences Ltd
+0.89%
+$4.29M 
BBNX Beta Bionics Inc.
+0.81%
+$81,455.5 
CMC Commercial Metals Company
+0.73%
+$32,160 
PTGX Protagonist Therapeutics Inc.
+0.7%
+$6.03M 
BIDU Baidu Inc.
+0.37%
+$361,135.5 
ARMK Aramark
+0.15%
+$290,058.48 
TNGX Tango Therapeutics Inc.
+0.09%
+$245,540 
ASMB Assembly Biosciences Inc.
+0.07%
+$24,068.85 
LNTH Lantheus Holdings, Inc.
+0.01%
+$55,834.79 
CRNX Crinetics Pharmaceuticals Inc.
0%
$0 
EA Electronic Arts Inc.
0%
$0 
PCSC Perceptive Capital Solutions, Inc.
0%
$0 CGC
CGC
0%
$0 5949
594972AN1
0%
$0 5949
594972AS0
0%
$0 
JATT JATT II Acquisition Corp
0%
$0 9013
90138AAE3
0%
$0 5949
594972AU5
0%
$0 
BGLWW Blue Gold Limited Warrant
-33.08%
-$3,299.82 
NVNIW Nvni Group Ltd. Warrant
-13.37%
-$862.5 
ANNAW Aleanna Inc.
-7.23%
-$18,612 
SNPS Synopsys, Inc.
-3.53%
-$14.04M 
TWST Twist Bioscience Corporation
-3.22%
-$10.19M 
RVMDW Revolution Medicines, Inc. Warrant
-3%
-$36,013.49 
VNET VNET Group Inc. American Depositary Receipt
-2.78%
-$249,000 
ANNA Aleanna Inc.
-2.64%
-$5,488 
PBLS Parabilis Medicines, Inc.
-2.57%
-$1.57M 
AVGO Broadcom Inc.
-2.3%
-$9.18M 
IFRX InflaRx N.V.
-2.03%
-$99,750 
PACB Pacific Biosciences of California, Inc.
-2.01%
-$568 
SMC Summit Midstream Corporation
-1.88%
-$33,181.98 
NERV Minerva Neurosciences Inc.
-1.7%
-$94,600 
WRBY Warby Parker Inc.
-1.65%
-$339,480 
GRAL Grail, Inc.
-1.62%
-$9.41M 
RVMD Revolution Medicines Inc.
-1.6%
-$42.01M 
ACHC Acadia Healthcare Company, Inc.
-1.55%
-$2.07M 
BTSGU BrightSpring Health Services, Inc. 6.75% Preferred Stock due 2027
-1.48%
-$5.3M 
RIO Rio Tinto Plc Sponsored ADR
-1.32%
-$221,087.37 
IMVT Immunovant Inc.
-1.23%
-$2M 
MOBI Mobia Medical, Inc.
-0.6%
-$56,427.85 
AMZN Amazon.com Inc
-0.22%
-$1.47M 
WAB Wabtec Corporation
-0.19%
-$491,967.7 
MRK Merck & Co., Inc.
-0.17%
-$48,755 
JNJ Johnson & Johnson
-0.05%
-$51,000 Events
Loading...
Dividends
Dividend Analysis
Loading...
No Data
| Trades 9148 | Longs Won 4534/9148 49% | Profit Factor 2.56 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $17.83M |
| Average Win $7.38M | Best Trade (Oct 14) $562.06M | Sharpe Ratio -107.35 |
| Average Loss -$2.83M | Worst Trade (Dec 30) -$562.55M | Z-Score -14.58 (100%) |
| Commissions $0 | Avg. Trade Length 1y 4w 1d | Expectancy $2.23M |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 6,369 | 5,732 | 5,096 | 4,459 | 3,822 | 3,185 | 2,548 | 1,911 | 1,274 | 637 |
Hover over the desired column for a detailed explanation.
Returns
Overall, Monthly| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
| 5949 594972AN1 | 15M | $14.19M | $14.19M | - | - | - | 0.0 |
| 5949 594972AS0 | 87.86M | $74.36M | $73.13M | - | -$1.23M | -1.66% | 0.0 |
| 5949 594972AU5 | 2.63M | $2.32M | $2.32M | - | - | - | 0.0 |
| 9013 90138AAE3 | 45M | $44.52M | $44.52M | - | - | - | 0.0 |
| ABVX Abivax SA ADR | 122,000 | $16.16M | $11.2M | - | -$4.96M | -30.69% | +4.359% |
| ACHC Acadia Healthcare Company, Inc. | 4.22M | $113.98M | $131.6M | - | $17.63M | 15.47% | -1.547% |
| AGIO Agios Pharmaceuticals Inc. | 5.92M | $172.83M | $191.31M | - | $18.48M | 10.7% | +4.391% |
| ALMR Alamar Biosciences, Inc. | 462,900 | $12.54M | $13M | - | $460,909.53 | 3.68% | +10.704% |
| ALVO Alvotech SA | 2.86M | $13.65M | $15.39M | - | $1.73M | 12.67% | +4.062% |
| AMZN Amazon.com Inc | 2.63M | $589.1M | $667.52M | - | $78.42M | 13.31% | -0.22% |
| ANNA Aleanna Inc. | 78,400 | $531,552 | $202,272 | - | -$329,280 | -61.95% | -2.642% |
| ANNAW Aleanna Inc. | 990,000 | $138,600 | $238,689 | - | $100,089 | 72.21% | -7.234% |
| AON Aon plc | 1.38M | $491.88M | $396.86M | - | -$95.01M | -19.32% | +4.249% |
| ARMK Aramark | 3.63M | $126M | $198.8M | - | $72.79M | 57.77% | +0.146% |
| ASMB Assembly Biosciences Inc. | 1.6M | $41.79M | $32.97M | - | -$8.82M | -21.11% | +0.073% |
| AVGO Broadcom Inc. | 1.15M | $366.18M | $389.63M | - | $23.45M | 6.4% | -2.302% |
| AVTX Avalo Therapeutics Inc. | 2.5M | $42.91M | $30.4M | - | -$12.51M | -29.15% | +2.787% |
| AXTA Axalta Coating Systems Ltd. | 478,000 | $16.36M | $16.1M | - | -$258,120 | -1.58% | +1.507% |
| AZN AstraZeneca PLC American Depositary Shares | 574,000 | $110.56M | $96.05M | - | -$14.51M | -13.12% | +3.277% |
| BBIO BridgeBio Pharma, Inc. | 10.74M | $465.12M | $723.76M | - | $258.64M | 55.61% | +3.742% |
No Data
Option values are updated at end of day.
No Data
No Data
Option values are updated at end of day.
No Data
No Data
No Data
No Data
FAQ
Which stocks have generated the highest profits for Farallon Capital?
The largest contributions to the portfolio's profits come from the following stocks: Alphabet Inc - $1.04B, Microsoft Corp - $869.07M, Wabtec Corporation - $557.25M, Visa Inc. Class A - $557.05M, and Salesforce Inc - $489.15M. These positions have been the main drivers of growth and have significantly impacted the investor's overall performance.
Which stocks have generated the largest losses for this investor?
The largest losses in the portfolio are associated with the following stocks: Altaba Inc - $1.18B, CSE - $537.12M, Block, Inc - $222.76M, 54975p102 - $211.28M, and Clarivate Plc - $177.62M. These positions have had the most negative impact on overall performance and highlight the weaker areas of the portfolio.
What dividends does Farallon Capital's portfolio generate?
The portfolio generates substantial dividend income, with a total of $1.42B earned over time. The largest contributors to dividend income include Corgi MU 2x Daily ETF - $163.05M, Veon Ltd - $138.53M, TransDigm Group Inc - $74.67M, Microsoft Corp - $64.71M, and Citigroup Inc - $51.26M. This indicates that dividends play a meaningful role in the investor's overall strategy.
How stable are Farallon Capital's monthly returns?
Farallon Capital's monthly returns appear quite volatile. The gap between stronger and weaker months is meaningful, which suggests that the strategy can experience noticeable swings over relatively short periods. For users assessing this profile, that usually means returns may be attractive over time, but the path can be uneven and harder to tolerate during weaker periods.
Can Farallon Capital's strategy be considered aggressive or moderate?
Farallon Capital's strategy appears moderately aggressive. The portfolio shows a clear focus on growth, with noticeable volatility and risk exposure, although not to an extreme level. This type of strategy may appeal to users seeking higher returns while accepting meaningful fluctuations along the way.
Should beginners follow Farallon Capital's strategy?
Farallon Capital's strategy is unlikely to be suitable for beginners. The portfolio shows signs of high risk, significant volatility, or structural complexity, which can make it difficult to follow and potentially stressful for less experienced users. This type of approach is generally better suited to more advanced investors.
2026 © Marketlog. All Rights Reserved.
